Sun Pharma Forecasts Promising Growth for FY25

Drug major Sun Pharmaceutical Industries anticipates a high single-digit growth in top line revenue for FY25. The company reported a consolidated revenue of Rs 48,497 crore for FY24. MD Dilip Shanghvi mentioned ongoing investments in product launches and R&D, aiming for sustained long-term growth.

Drug major Sun Pharmaceutical Industries is projecting a high single-digit growth in its top line revenue for FY25, as stated by Managing Director Dilip Shanghvi.

The Mumbai-based pharmaceutical giant reported a consolidated total revenue of Rs 48,497 crore for FY24, compared to Rs 43,886 crore in FY23.

Shanghvi disclosed that the company is in the investment phase for several of its businesses, particularly focusing on product launches in the US and ramping up its global specialty business.

"We expect high single-digit consolidated top line growth for FY25. All our businesses are positioned for robust growth," Shanghvi said during an analyst call.

He noted that R&D investments will account for 8-10 percent of sales this year, emphasizing the need to invest in future growth without compromising profitability. Shanghvi also highlighted Sun Pharma's strong market position, ranked number one with an 8.5 percent market share in India's Rs 1,970-billion pharmaceutical market.

For the fiscal year ended March 31, 2024, Sun Pharma reported a consolidated net profit of Rs 9,576 crore, up from Rs 8,474 crore in the previous fiscal year.

(This story has not been edited by Devdiscourse staff and is auto-generated from a syndicated feed.)